This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

This study has been completed.
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: February 28, 2013
Last updated: NA
Last verified: February 2013
History: No changes posted
This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.

Condition Intervention Phase
Systemic Juvenile Idiopathic Arthritis Drug: rilonacept (IL-1 Trap) Other: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Resource links provided by NLM:

Further study details as provided by Regeneron Pharmaceuticals:

Primary Outcome Measures:
  • Frequency of treatment emergent adverse events (TEAEs) [ Time Frame: Baseline to Week 123 ]

Enrollment: 24
Study Start Date: November 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Dose 1
Drug: rilonacept (IL-1 Trap) Other: Placebo
Experimental: Cohort 2
Dose 2
Drug: rilonacept (IL-1 Trap) Other: Placebo


Ages Eligible for Study:   4 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria include, but are not limited to, the following:

  • Patients aged 4 to less than 21 years who meet the criteria for active SJIA
  • Must have been on a stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks prior to the screening visit

Exclusion Criteria include, but are not limited to, the following:

  • Use of certain medications prior to the baseline visit
  • History of recurrent infections
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01803321

United States, California
Los Angeles, California, United States
United States, Delaware
Wilmington, Delaware, United States
United States, Illinois
Chicago, Illinois, United States
United States, New Jersey
Hackensack, New Jersey, United States
United States, New York
Long Island, New York, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
United States, Texas
Dallas, Texas, United States
United States, Washington
Seattle, Washington, United States
Sponsors and Collaborators
Regeneron Pharmaceuticals
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Regeneron Pharmaceuticals Identifier: NCT01803321     History of Changes
Other Study ID Numbers: IL1T-AI-0504
Study First Received: February 28, 2013
Last Updated: February 28, 2013

Keywords provided by Regeneron Pharmaceuticals:

Additional relevant MeSH terms:
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017